SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-009629
Filing Date
2023-03-29
Accepted
2023-03-29 07:32:42
Documents
14
Period of Report
2023-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20230329.htm   iXBRL 8-K 29464
2 EX-99.1 ex-991fy22earningsrelease.htm EX-99.1 108602
6 GRAPHIC avalo-logoxblk1.jpg GRAPHIC 99614
  Complete submission text file 0001628280-23-009629.txt   413896

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230329.xsd EX-101.SCH 1967
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230329_lab.xml EX-101.LAB 24181
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230329_pre.xml EX-101.PRE 12574
8 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230329_htm.xml XML 3955
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 23771774
SIC: 2834 Pharmaceutical Preparations